How DNA methylation predicts response to cancer therapies
Trends in Cancer · 2026-07 · 12 (7) · 598-620
DOI: 10.1016/j.trecan.2026.04.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2026-07. Verfasst von Veronica Davalos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain. Electronic address: vdavalos@carrerasresearch.org. Hauptthemen laut MEDLINE: DNA Methylation, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Generalitat de Catalunya Departament d'Innovacio Universitats I Empresa, State Agency of Research.
Abstract (Originalsprache)
Aberrant DNA methylation is a hallmark of cancer. Beyond its established diagnostic applications, growing evidence supports the utility of DNA methylation in predicting therapeutic response. By modulating gene expression patterns, particularly in pathways related to drug metabolism, DNA repair, and immune response, methylation profiles can directly influence how tumors respond to specific treatments. Although clinical implementation remains limited to a few examples, ongoing efforts to standardize assays, enhance sensitivity in liquid biopsy, and validate predictive markers in prospective trials will enable its full recognition as a dynamic, actionable decision-support tool for therapy selection and adaptive management of cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain. Electronic address: vdavalos@carrerasresearch.org.
- Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain; Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Barcelona, Catalonia, Spain; Karches Center for…
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain; Cancer Epigenetics, Sant Pau Research Institute (IR Sant Pau), Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (I…
Förderung
- Instituto de Salud Carlos III
- Generalitat de Catalunya Departament d'Innovacio Universitats I Empresa
- State Agency of Research
- José Carreras Leukämie-Stiftung
- Institució Catalana de Recerca i Estudis Avançats
- CLL Global Research Foundation
- Ministerio de Ciencia, Innovación y Universidades
- European Commission
Zitieren
APA
Davalos, V., Ferrer, G., & Esteller, M. (2026). How DNA methylation predicts response to cancer therapies. Trends in Cancer, 12(7), 598-620. https://doi.org/10.1016/j.trecan.2026.04.002
Vancouver
Davalos V, Ferrer G, Esteller M. How DNA methylation predicts response to cancer therapies. Trends in Cancer. 2026;12(7):598-620. doi:10.1016/j.trecan.2026.04.002
BibTeX
@article{Davalos2026,
author = {Davalos, Veronica and Ferrer, Gerardo and Esteller, Manel},
title = {How DNA methylation predicts response to cancer therapies},
journal = {Trends in Cancer},
year = {2026},
volume = {12},
number = {7},
pages = {598--620},
doi = {10.1016/j.trecan.2026.04.002}
}
EUVIMED